Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FP-101 for Vasomotor Symptoms
NCT03285672Phase 2Completed
- Sponsor
- Fervent Pharmaceuticals
- Start
- Mar 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of FP-101 in vasomotor symptoms, sponsored by Fervent Pharmaceuticals. Started Mar 2018; status: completed.
02
Drugs
FP-101
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT03285672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03285672.